Literature DB >> 23176118

Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells.

J Dirks1, A Egli, U Sester, M Sester, H H Hirsch.   

Abstract

BACKGROUND: Programmed death receptor-1 (PD-1) compromises cytomegalovirus (CMV)-specific T-cell responses and has been linked to CMV viremia after transplantation. An impaired functional and proliferative capacity of PD-1-positive CMV-specific T cells may be reversed by the antibody-mediated blockade of PD-1 signaling. However, knowledge is limited on changes in "cytokinome" expression profiles associated with reversal of functional exhaustion.
METHODS: The "cytokinome" was analyzed by 27-plex Luminex technology comparing renal transplant recipients with low (n = 5) and high (n = 5) PD-1 expression on CMV-specific T cells. The effect of blocking PD-1 by PD-ligand (PD-L) antibodies on restoration of cytokine expression was examined.
RESULTS: CMV-specific cytokine release and proliferation was lower in patients with high PD-1 expression on CMV-specific T cells. Antibody-mediated blockade of PD-L in CMV-stimulated samples restored expression levels of interleukin (IL)-1β, IL-2, IL-6, IL-9, IL-10, granulocyte colony-stimulating factor, interferon-γ, macrophage inflammatory protein-1α, and tumor necrosis factor-α. By contrast, no profound effect was observed for controls or patients with low PD-1 expression, or in staphylococcal enterotoxin B-stimulated cells.
CONCLUSION: Taken together, this pilot study provides evidence that a high PD-1 expression on CMV-specific T cells actively impairs proliferation and "cytokinome" responses in an antigen-specific manner. Importantly, blockade of PD-L restores CMV-specific T-cell proliferation and expression of a panel of different proinflammatory and/or type 1 cytokines, suggesting a common but as yet unknown regulatory principle. We conclude that PD-1 exhaustion is reversible and potentially amenable to therapeutic ex vivo and possibly in vivo manipulation. However, detailed knowledge of the differential effects on the "cytokinome" will be necessary to increase the safety and the efficacy of such manipulations.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23176118     DOI: 10.1111/tid.12025

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  18 in total

1.  Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity.

Authors:  Yongkui Li; Min Fang; Jian Zhang; Jian Wang; Yu Song; Jie Shi; Wei Li; Gang Wu; Jinghua Ren; Zheng Wang; Weiping Zou; Lin Wang
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

Review 2.  Multiple Drug Hypersensitivity.

Authors:  Werner J Pichler; Yuttana Srinoulprasert; James Yun; Oliver Hausmann
Journal:  Int Arch Allergy Immunol       Date:  2017-03-18       Impact factor: 2.749

3.  NF-κB regulates PD-1 expression in macrophages.

Authors:  Alexander P R Bally; Peiyuan Lu; Yan Tang; James W Austin; Christopher D Scharer; Rafi Ahmed; Jeremy M Boss
Journal:  J Immunol       Date:  2015-03-25       Impact factor: 5.422

Review 4.  Advances in immunotherapy delivery from implantable and injectable biomaterials.

Authors:  David G Leach; Simon Young; Jeffrey D Hartgerink
Journal:  Acta Biomater       Date:  2019-02-13       Impact factor: 8.947

Review 5.  Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.

Authors:  Thomas Powles; Andrea Necchi; Galit Rosen; Subramanian Hariharan; Andrea B Apolo
Journal:  Clin Genitourin Cancer       Date:  2017-12-06       Impact factor: 2.872

Review 6.  Impact of sepsis on CD4 T cell immunity.

Authors:  Javier Cabrera-Perez; Stephanie A Condotta; Vladimir P Badovinac; Thomas S Griffith
Journal:  J Leukoc Biol       Date:  2014-05-02       Impact factor: 4.962

7.  Alterations in antigen-specific naive CD4 T cell precursors after sepsis impairs their responsiveness to pathogen challenge.

Authors:  Javier Cabrera-Perez; Stephanie A Condotta; Britnie R James; Sakeen W Kashem; Erik L Brincks; Deepa Rai; Tamara A Kucaba; Vladimir P Badovinac; Thomas S Griffith
Journal:  J Immunol       Date:  2015-01-16       Impact factor: 5.422

8.  Characterization of T cell immunophenotypes in intestinal transplantation: A pilot study.

Authors:  Marjorie-Anne R Guerra; Maura Rossetti; Zhenyu Zhang; Xinkai Zhou; Emily C Whang; Robert S Venick; Elizabeth A Marcus; Suzanne V McDiarmid; Douglas G Farmer; Elaine F Reed; Laura J Wozniak
Journal:  Transpl Immunol       Date:  2018-09-20       Impact factor: 1.708

9.  Cytokine release syndrome after radiation therapy: case report and review of the literature.

Authors:  Christopher A Barker; Samuel K Kim; Sadna Budhu; Konstantina Matsoukas; Anthony F Daniyan; Sandra P D'Angelo
Journal:  J Immunother Cancer       Date:  2018-01-03       Impact factor: 13.751

Review 10.  Is immunosenescence influenced by our lifetime "dose" of exercise?

Authors:  James E Turner
Journal:  Biogerontology       Date:  2016-03-29       Impact factor: 4.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.